Novel Targeted Iodinated Microbubbles for Molecular Imaging With Computed Tomography

项目总结 精准医疗为每个人提供个性化的疾病治疗和预防策略。分子 成像(MI)在精确医学中发挥着关键作用，因为它可视化了潜在的生物过程 每个人都有独特的疾病发展。MI需要以进程为目标的成像探测器 例如血管生成和炎症，并报告体内活动的位置。当前的临床前阶段 (超声)和临床(正电子发射断层扫描)心肌梗死的应用有身体受限的缺点。 覆盖率和空间分辨率分别较低。计算机断层扫描(CT)产生高分辨率的3- 三维全身图像但已落后于其他MI模式，因为它缺乏临床可行的 靶向成像探头。这项研究的长期目标是适应和增强现有的、随时可用的 通过引入针对疾病的成像探针，用于临床分子成像的成像方式，CT 可被X射线检测到的。这个项目的具体目标有两个方面。第一个目标是开发一种新型的CT分子 结合已建立的靶向微泡造影剂平台用于超声显像剂 用用CT可检测到的独特的脂肪族碘化单体合成的不透射线聚酯来生产 靶向碘化微泡(TIMB)。TIMBS的对比度特性将与碘进行比较。 负荷、温度和浓度。第二个目标是在活体模型中测试TIMB和CT参数 并比较超声心动图对血管生成的敏感性。这个项目的结果将是TIMB，一个有针对性的 CT造影剂，可作为早期发现的工具，从根本上提高治疗效果 和预防疾病。这是将CT确立为临床上可行的分子选择的第一步 成像促进了高分辨率全身分子成像，这是推动精准医学所需的。

PROJECT SUMMARY Precision medicine individualizes disease treatment and prevention strategies for each person. Molecular imaging (MI) plays a key role in precision medicine because it visualizes the biological processes underlying the development of disease that are unique to each individual. MI requires an imaging probe that targets processes like angiogenesis and inflammation and reports the location of the activity inside the body. Current preclinical (ultrasound) and clinical (positron emission tomography) MI applications have the drawbacks of limited body coverage and poor spatial resolution, respectively. Computed tomography (CT) produces high-resolution 3- dimensional whole body images but has fallen behind other MI modalities because it lacks a clinically viable targeted imaging probe. The long-term goal of this research is to adapt and enhance an existing, readily available imaging modality, CT, for clinical molecular imaging by introducing an imaging probe that targets disease and is detectable by x-ray. The specific aims of this project are 2-fold. The first aim is to develop a novel CT molecular imaging agent by combining the established platform of targeted microbubble contrast agents used in ultrasound with radiopaque polyesters synthesized with a unique, aliphatic, iodinated monomer detectable by CT to produce targeted iodinated microbubble (TIMb). The radio-contrast properties of TIMbs will be evaluated versus iodine loading, temperature and concentration. The second aim is to test TIMb and CT parameters in an in vivo model of angiogenesis and compare sensitivity to ultrasound MI. The outcome of this project will be TIMb, a targeted contrast agent for CT, which can be used as a tool for early detection, fundamentally improving the treatment and prevention of disease. This is the first step toward establishing CT as a clinically viable option for molecular imaging to facilitate high-resolution whole body molecular imaging needed in the push toward precision medicine.